Last reviewed · How we verify

NCT05436860

PreDEA Study, Prevention in Emergency / Acceptance Departments: the Case of Hepatic Steatosis

Status unknown Last updated 5 December 2023
What this trial tests

trial testing liver ultrasound in Hepatic Steatosis in 20,189 participants. Status unknown.

Timeline
1 July 2023
Primary endpoint
31 December 2023
1 July 2024

Quick facts

Lead sponsorUniversity of L'Aquila
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment20,189
Start date1 July 2023
Primary completion31 December 2023
Estimated completion1 July 2024
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of L'Aquila

Who can join

18 and older, any sex, with Hepatic Steatosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study aims to evaluate whether the Emergency Department (PS) can support the health system to improve the prevention and management of chronic inflammatory diseases and ensure actions aimed at screening, raising awareness and informing the population. Specifically, the determination of the prevalence of a widely diffused pathology such as fatty liver disease aims to be the precursor of future pilot studies aimed at evaluating the advantages and critical issues of the PS as a prevention tool.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatic Steatosis

Currently open trials in the same condition.

Other University of L'Aquila trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05436860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing